Mitochondrial membrane stabilizer

Details Mitochondrial membrane stabilizer Mitochondrial membrane stabilizer

1999-05-26

2002-07-09

Krass, Frederick (Department: 1614)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C514S258100, C514S259500, C514S260100, C514S291000, C514S293000, C514S294000, C514S307000, C514S309000, C514S310000, C514S311000, C514S312000, C514S313000, C514S314000, C514S317000, C514S618000, C514S619000, C514S620000, C514S233200, C514S267000

Reexamination Certificate

active

06417220

ABSTRACT:

This application is a 371 of PCT/JP97/03485, filed Sep. 30, 1997.
TECHNICAL FIELD
The present invention relates to a medicament for prophylactic and/or preventive and/or therapeutic treatment of diseases caused by mitochondrial functional abnormality or diseases with mitochondrial functional abnormality.
BACKGROUND ART
It is known that intracellular calcium ions (Ca
+2
) may become a cytotoxic factor when increased beyond a certain concentration, although they act as an important information transmitter under physiological conditions. In particular, in the nervous system under ischemic conditions, calcium ions flow into cells through the glutamic acid receptor (NMDA type) due to excessive glutamic acid and induce nerve necrosis (Choi, D. W., Trends in Neurosciences, 11, 465-469, 1988). Under healthy conditions, excessive calcium ions are taken into the endoplasmic reticulum and mitochondria when calcium ions flow into cells beyond a certain concentration, and as a result, calcium ion concentrations are homeostatically maintained.
However, when high levels of calcium ions are accumulated in mitochondria for a prolonged period of time and chronic hypoxic conditions are maintained in mitochondria, the mitochondrial energy-generating function (ability to synthesize ATP) becomes degraded, which results in stoppage of various ion pumps present in cellular membranes (Nicotera et al., Chem. Res. Toxico., 3, 484-494, 1990; and Zaiden et al., J. Neurochem., 63, 1812-1819, 1994). In addition, when the state of calcium ion influx is maintained, plasma membranes are depolarized. This may cause disinhibition of NMDA-type glutamate receptor/ion channel complex that is kept in a suppressed condition by magnesium ions, which leads to further acceleration of calcium ion influx as a vicious circle.
If the mitochondrial energy-generating function (ATP synthesis) can be maintained even at the condition of influx and accumulation of a high level of calcium ions in mitochondria, the function of the calcium ion pumps, that are present in plasma membranes, can be kept normal and concentrations of the influxed and accumulated calcium ions in the cells can be lowered. As a result, physiological conditions of the cells may be restored. However, it has been considered that the activation of the mitochondria is substantially impossible under the calcium influx by the reasons set out below.
Energy generation in mitochondria is performed by the process of aerobic glycolysis (TCA cycle). Protons (H
+
) are produced in the process (electron transfer system), and the generated energy is used to transfer the protons from the inner matrix of mitochondria to the outside.
Extremely high electrochemical potentials are generated across the mitochondrial inner membrane from the outside {1) mitochondrial membrane potentials (&PSgr;m) approximately −150 mV and 2) chemical potentials derived from the difference in proton (H
+
) concentration across the mitochondrial inner membrane} (Loew et al., Proc. Natl. Acad. Sci., USA, 91, 12579-12583, 1994). The high potential energies based on the active transport of protons (H
+
) is then used to drive ATP synthesis (Kagawa, Y., Saibo Kogaku (Cell Technology), 11, 3-11, 1992).
However, under physiological conditions, when positively charged calcium ions flow into the mitochondrial matrix, these calcium ions are pumped out by consuming the energy generated by ATPase located in the mitochondrial matrix, so that the mitochondrial membrane potential can be maintained. However, under pathological conditions where ATP activity is degraded, ATPase activity is decreased and the pumping out of calcium ions may become insufficient, so that the potential of the mitochondrial matrix shifts to the positive, thereby reducing &PSgr;m (decrease of electrical potential).
Under these pathological conditions (a state of depolarized mitochondrial membrane potential), even though the chemical potential generated by the proton (H
+
) gradient exists, a decrease in the electrochemical potential due to the lowered electrical potential (&PSgr;m) may cause inhibition of the activities of ATP synthase, which finally results in cessation of the mitochondrial ATP synthesis.
It has been suggested that mitochondrial membranes may be depolarized by various exogenous and endogenous factors, and the depolarization may possibly be one cause of mitochondrial functional abnormality. Furthermore, mitochondrial functional abnormality is observed in various diseases, and the abnormality of mitochondrial function is considered as a major cause of some diseases. For example, the abnormality of mitochondrial function is generally recognized in ischemic diseases such as ischemic brain diseases and ischemic heart diseases, Parkinson's disease, Alzheimer's disease, amyotrophic lateral sclerosis (ALS), degenerative diseases due to mitochondrial abnormality such as mitochondrial encephalomyopathy, various toxic diseases such as carbon monoxide poisoning. A substance, which stabilizes mitochondrial membranes by protecting mitochondrial membranes from actions of various exogenous and endogenous factors and maintaining the physiological membrane potential, may be expected to be extremely useful for therapeutic and preventive and prophylactic treatment of these diseases.
DESCRIPTION OF THE INVENTION
An object of the present invention is to provide a substance which has an action of stabilizing mitochondrial membranes by protecting the mitochondrial membranes from actions of various exogenous and endogenous factors, and suppressing or eliminating the depolarization of mitochondrial membranes. Another object of the present invention is to provide a substance having actions of stabilizing mitochondrial membranes, and preventing the abnormality of mitochondrial function with depolarization of mitochondrial membranes. A further object of the present invention is to provide a medicament for prophylactic and/or preventive and/or therapeutic treatment of diseases caused by mitochondrial functional abnormality, or diseases with mitochondrial functional abnormality, which comprises a substance having the aforementioned actions as an active ingredient.
The inventors of the present invention conducted various studies to achieve the foregoing objects, and as a result, they first discovered the existence of a substance which has an action of stabilizing mitochondrial membranes by suppressing or eliminating the depolarization of mitochondrial membranes. The inventors of the present invention conducted further studies and found that, by stabilizing mitochondrial membranes, mitochondrial membranes can be protected from depolarization due to various exogenous and endogenous factors, and/or the physiological polarization condition of mitochondrial membranes can be maintained or restored, thereby physiological energy generation of mitochondria can be maintained or restored. It was also found that a substance having these actions can suppress an action of an agonist, that unstabilizes mitochondrial membrane, by binding as an antagonist to a benzodiazepine receptor present in mitochondrial membranes. The present invention was achieved on the bases of these findings.
The present invention thus provides a medicament for prophylactic and/or preventive and/or therapeutic treatment of a disease caused by mitochondrial functional abnormality, or a disease with mitochondrial functional abnormality, which comprises a substance having stabilizing effect on a mitochondrial membrane as an active ingredient. According to preferred embodiments of the aforementioned medicament of the present invention, there are provided the aforementioned medicament for prophylactic and/or preventive and/or therapeutic treatment wherein the stabilizing effect on the mitochondrial membrane is an action of suppressing or eliminating the depolarization of a mitochondrial membrane; the aforementioned medicament for prophylactic and/or preventive and/or therapeutic treatment wherein the depolarization of the mitochondrial membrane is c

Affiliated with

Also associated with

Rating

Mitochondrial membrane stabilizer does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Mitochondrial membrane stabilizer, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Mitochondrial membrane stabilizer will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2896522